You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.
The deal enables Genosity to add Olink's proteomics technology with next-generation sequencing readout to its repertoire of services.
The deal makes WuXi NextCode the exclusive provider of Olink's proteomics products in China, which the company will offer on a fee-for-service basis.
The study is enrolling up to 2,000 patients at 10 US medical centers and using omics approaches to profile their immune response over the course of a year.
According to the company, the NGS approach will allow it to lower assay costs while increasing its throughput and multiplexing capabilities.
Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.
High throughput and deep coverage have allowed firms like Olink and Somalogic to make inroads, especially among researchers working outside proteomics.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.